8-K: Anika Therapeutics' Hyalofast Phase III Misses Primary Endpoints, Plans H2 2025 FDA Filing

Anika Therapeutics announced its Hyalofast Phase III study missed co-primary endpoints for pain and function but showed statistically significant improvements in secondary measures, with plans to file the final PMA module in H2 2025.

Summary

• Anika Therapeutics announced topline results from its U.S. pivotal FastTRACK Phase III study for Hyalofast cartilage repair scaffold.
• The study, which completed enrollment in 2023 and two-year follow-up recently, evaluated Hyalofast with autologous BMAC against microfracture control.
• Hyalofast consistently improved over microfracture but did not meet the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function from baseline to two years.
• The study's statistical analysis was complicated by a higher subject dropout rate in the microfracture arm and missed visits during COVID, leading to missing data and reduced evaluable sample size.
• Hyalofast demonstrated statistically significant improvements in key pre-defined secondary endpoints, including KOOS Sports and Recreation Function, Quality of Life, and Total KOOS.
• These secondary measures align with prior FDA approvals for cartilage repair products.
• Hyalofast has been used to treat over 35,000 patients in more than 35 countries outside the U.S. since 2009, with positive 15-year outcomes published last year.
• The company plans to file the third and final PMA module in the second half of 2025, including additional post-hoc analyses and data from outside the U.S.
• Hyalofast has a Breakthrough Device Designation from the FDA.

Sentiment

Score: 4

Explanation: The primary endpoints were missed, which is a significant negative for a Phase III trial. However, the company still plans to file for FDA approval based on strong secondary endpoints and extensive international real-world data, which mitigates some of the negative impact. The Breakthrough Device Designation also offers a pathway for approval despite the primary endpoint miss.

Positives

• Hyalofast consistently demonstrated improvements over microfracture across all measures of pain and function.
• Achieved statistically significant improvements in key pre-defined secondary endpoints: KOOS Sports and Recreation Function, Quality of Life, and Total KOOS.
• These secondary measures have supported prior FDA approvals for cartilage repair products.
• Hyalofast exhibited a comparable safety profile to microfracture, supporting a favorable benefit-risk profile.
• Over 35,000 patients treated in more than 35 countries outside the U.S. since 2009, with a favorable safety and effectiveness profile from real-world clinical experience, including positive 15-year outcomes.
• Hyalofast has been designated as a breakthrough device by the FDA, allowing prioritized interaction and review.
• Company still plans to file the final PMA module in H2 2025 based on the totality of data.

Negatives

• Hyalofast missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function.
• The study was likely impacted by a higher subject dropout rate in the microfracture arm and missed visits during COVID, leading to missing data and reduced evaluable sample size.

Risks

• The company's ability to timely complete regulatory submissions, including the third PMA module for Hyalofast.
• The FDA's ability to timely review any such submission.
• The FDA may not approve the Hyalofast PMA because of the failure to achieve the pre-defined primary endpoints.
• The FDA may determine that achievement of secondary endpoints and/or post hoc data analyses are not sufficient to support approval.

Future Outlook

Anika plans to file the third and final PMA module for Hyalofast in the second half of 2025, seeking FDA approval. The company expects the FDA to consider additional post-hoc analyses and data from outside the U.S. as part of its review under the Breakthrough Device Designation, though sufficiency for approval remains a review issue.

Management Comments

• While we are disappointed that the co-primary endpoints were not achieved under the original statistical framework, we are encouraged by the consistency and robustness of our results on pain and function measures including achieving significance on measures used for prior FDA cartilage repair approvals and the published global evidence supporting the safety and effectiveness of Hyalofast.
• We believe the totality of evidence presented in this study and the data from outside the U.S. demonstrates the true clinical value of Hyalofast, a single stage procedure, for patients who suffer from cartilage lesions in the knee.

Industry Context

The announcement relates to the orthopedic regenerative solutions market, specifically for cartilage repair. Hyalofast, a hyaluronic acid scaffold, competes with existing treatments like microfracture and other cartilage repair products. Its long-standing international use and Breakthrough Device Designation suggest a potentially significant entry into the U.S. market if approved, addressing a need for single-stage procedures for knee cartilage lesions.

Comparison to Industry Standards

• Hyalofast's statistically significant improvements in secondary endpoints (KOOS Sports and Recreation Function, Quality of Life, Total KOOS) align with measures that have supported prior FDA approvals for other cartilage repair products.
• The filing does not name specific comparable companies or projects, but it implies that the achieved secondary endpoints are consistent with the bar set by previously approved cartilage repair solutions.

Stakeholder Impact

• Shareholders: Potential negative impact due to missed primary endpoints, but mitigated by continued FDA filing plans and positive secondary data. Future share price will depend on FDA approval.
• Patients: Potential positive impact if Hyalofast receives FDA approval, offering a new single-stage treatment option for knee cartilage lesions with a favorable safety profile and demonstrated effectiveness outside the U.S.

Next Steps

• Anika plans to file the third and final PMA module for Hyalofast in the second half of 2025.
• The third module will include ongoing additional post-hoc analyses, including consideration of additional endpoints previously accepted by the FDA for cartilage repair product approvals.
• The FDA will review the PMA submission, considering the additional post-hoc analyses and data from outside the U.S.

Key Dates

Recommendation

While the primary endpoints were missed, which is a significant setback, the company's commitment to filing for FDA approval based on strong secondary endpoints and extensive real-world data from international markets provides a potential path forward. The Breakthrough Device Designation could also facilitate approval. However, the uncertainty surrounding FDA approval given the primary endpoint miss warrants a cautious "hold" recommendation until the FDA's decision is known. The stock could see volatility based on market reaction to the primary endpoint miss versus the continued pursuit of approval.

Keywords

Anika Therapeutics, ANIK, Hyalofast, cartilage repair, Phase III, clinical trial, FDA approval, medical device, orthopedics, regenerative medicine, osteoarthritis, knee injury, microfracture, PMA submission, breakthrough device